NASDAQ:DRMA

Dermata Therapeutics Q1 2026 Earnings Results & Report

Dermata Therapeutics logo
$0.57 -0.03 (-4.75%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.58 +0.01 (+1.56%)
As of 11/17/2026 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dermata Therapeutics beat analyst earnings expectations in its Q1 2026 results, released May 13, 2026. The company reported EPS of -$0.48 versus the -$0.53 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Dermata Therapeutics EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.53
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Dermata Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Dermata Therapeutics' Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

Dermata Therapeutics Q1 2026 Earnings FAQ

Dermata Therapeutics (NASDAQ:DRMA) reported earnings of -$0.48 per share for Q1 2026, beating the consensus estimate of -$0.53. The report was announced on Wednesday, May 13, 2026.

Dermata Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Dermata Therapeutics on the company's earnings history page.

Dermata Therapeutics Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Dermata Therapeutics (DRMA) Set to Announce Quarterly Earnings on Wednesday
See More Dermata Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dermata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dermata Therapeutics and other key companies, straight to your email.

About Dermata Therapeutics

Dermata Therapeutics (NASDAQ:DRMA) is a clinical-stage biopharmaceutical company focused on developing treatments for skin conditions. The San Diego-based company uses a proprietary technology derived from freshwater sponges to develop topical therapies.

Its lead candidate, DMT310, is an investigational topical treatment being developed for acne. Dermata has also developed DMT410, a candidate that combines its sponge-based technology with botulinum toxin for potential use in dermatologic conditions. These candidates are investigational and have not been approved for marketing.

View Dermata Therapeutics Profile